Introduction {#s1}
============

Breast cancer (BrC) is the second most common cancer worldwide and the most frequent cancer among women. Despite advances in screening, early diagnosis, and treatment strategies, BrC still constitutes the leading cause of cancer-related death among women ([@B5]). BrC is a highly heterogeneous disease with distinct biological features and clinical outcomes. Based on gene expression profiling, BrC is often classified into four well-established intrinsic subtypes ([**Table 1**](#T1){ref-type="table"}) ([@B55]; [@B43]). However, due to logistic and economical constraints, surrogate approaches have been developed for routine clinical practice, using widely available immunohistochemistry (IHC) assays for estrogen receptor (ER), progesterone receptor (PR), and Ki-67 *index*, together with IHC and/or *in situ* hybridization for human epidermal growth factor 2 receptor (HER2) overexpression/amplification ([@B50]).

###### 

Breast cancer molecular subtypes characterization ([@B44]; [@B56]; [@B42]; [@B16]; [@B20]; [@B40]; [@B24]; [@B66]; [@B50]).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Breast cancer subtypes   Clinicopathological surrogate markers   Signature genes                                                                Adjuvant systemic therapeutic options                                                            
  ------------------------ --------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ --------------------------------
  **Luminal A**            ER^+^\                                  *ESR1* and/or *PGR*, *KRT8*/18, *GATA3*, *XBP1*, *FOXA1*, and *ADH1B*          ET alone in most of cases + ChT if high tumor burden (≥N3, ≥T3)                                  
                           PR high^1^\                                                                                                                                                                                                             
                           HER2^-^\                                                                                                                                                                                                                
                           Ki-67 low^2^                                                                                                                                                                                                            

  **Luminal B**            **HER2^-^**                             ER^+^\                                                                         *ESR1* and/or *PGR*, *KRT*8/18, *FGFR1*, *ERBB1*, *MKI67* and/or *CCNE1*, *CCNB1*, and *MYBL2*   ET + ChT for the most of cases
                                                                   HER2^-^\                                                                                                                                                                        
                                                                   Ki-67 high or PR low                                                                                                                                                            

  **HER2^+^**              ER^+^\                                  ChT + anti-HER2 + ET for all patients                                                                                                                                           
                           HER2^+^\                                                                                                                                                                                                                
                           Any Ki-67\                                                                                                                                                                                                              
                           Any PR                                                                                                                                                                                                                  

  **Basal-like**           ER^-^\                                  *KRT*5/6, *KRT*17, *ERBB1* and/or *KIT*, FOXC1, TP63, *CDH3*, VIM, and *LAM*   ChT                                                                                              
                           PR^-^\                                                                                                                                                                                                                  
                           HER2^-^                                                                                                                                                                                                                 

  **HER2-enriched**        HER2^+^\                                *ERBB2* and *GRB7*                                                             ChT + anti-HER2                                                                                  
                           ER^-^\                                                                                                                                                                                                                  
                           PR^-^                                                                                                                                                                                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Suggested cutoff value is 20%. ^2^Ki-67 scores should be interpreted in the light of local laboratory median values. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ESR1, estrogen receptor 1; PGR, progesterone receptor; KRT, keratin; GATA3, GATA binding protein 3; XBP1, X-box binding protein 1; FOX, forkhead box; ADH1B, alcohol dehydrogenase 1B (Class I), beta polypeptide; FGFR1, fibroblast growth factor receptor 1; ERBB, Erb-B2 receptor tyrosine kinase; MKI67, marker of proliferation Ki-67; CCN, cyclin; MYBL2, MYB proto-oncogene like 2; MYBL2, MYB proto-oncogene like 2; KIT, KIT proto-oncogene receptor tyrosine kinase; TP63, tumor protein P63; CDH, cadherin; VIM, vimentin; LAM, laminin; GRB7, growth factor receptor bound protein 7; ChT, chemotherapy; ET, endocrine therapy; N, nodal stage; T, tumor size.

In addition to surgery, therapeutic strategies for BrC patients include neoadjuvant, adjuvant, and palliative treatments. Adjuvant systemic therapy, aiming to prevent BrC recurrence by eradicating micrometastases present at diagnosis, includes three modalities: chemotherapy, anti-HER2 therapy (e.g., trastuzumab), and endocrine therapy (ET). ER and HER2 *status* are used as predictive factors to select patients for specific adjuvant therapies ([**Table 1**](#T1){ref-type="table"}). ET, which blocks ER activation, is recommended for patients with ER-positive disease, to stop or slow the growth of hormone-sensitive BrC ([@B14]). Most luminal A BrC tumors do not require adjuvant chemotherapy, except those with the highest risk of relapse, whereas most luminal B tumors, especially those with HER2 overexpression, benefit from chemotherapy in addition to trastuzumab ([@B52]). Although ET results in substantial improvement of patients' outcome, resistance to treatment is a major hurdle ([@B66]), affecting 30--40% of ER-positive BrC patients, with all those treated in the metastatic setting eventually progressing ([@B41]; [@B39]). According to the 3rd ESO--ESMO International Consensus Guidelines, endocrine resistance may be defined as primary endocrine resistance, when patients relapse within the first 2 years of adjuvant ET, or as secondary (acquired) endocrine resistance, when patients relapse while on adjuvant ET after the first 2 years of treatment or within 12 months after completing treatment ([@B8]).

MicroRNAs (miRNAs), a class of small (∼22 nucleotides) non-coding single-stranded RNAs, have shown promise for assisting in clinical management of BrC as diagnostic, prognostic, or predictive biomarkers ([@B2]), namely, through assessment in liquid biopsies (plasma, serum, and urine) ([@B49]). Indeed, several studies have associated miRNAs deregulation with endocrine resistance and prognosis in luminal BrC ([@B47]; [@B37]; [@B3]; [@B38]). Whereas decreased ER expression and endocrine resistance may be due to *miR-221/222* overexpression ([@B68]; [@B46]; [@B60]; [@B54]), *miR-342-3p* expression positively correlated with ER mRNA transcript levels, being downregulated in tamoxifen-refractory BrC ([@B12]). Moreover, miRNAs regulating growth, survival, and apoptosis of BrC cells may also be implicated in loss of responsiveness to ET by endowing tumor cells with alternative proliferative and survival stimuli ([@B57]). Indeed, *miR-519a* associated with worse prognosis in luminal BrC patients, directly targeting the transcripts of *cyclin dependent kinase inhibitor 1A* (*CDKN1A*) and *phosphatase and tensin homolog* (*PTEN*), allowing for enhanced signaling of the *phosphoinositide3-kinase* (PI3K) growth and survival pathway ([@B59]) and reducing sensitivity and tumor cell apoptosis in response to apoptotic stimuli ([@B6]). Furthermore, miRNA-mediated endocrine resistance might be related with epithelial-to-mesenchymal transition (EMT) and metastatic potential of BrC cells, as members of the *miR-200family(miR-200f)*, which act as major regulators of EMT, were found downregulated in endocrine-resistant BrC *vs*. endocrine-sensitive cell lines ([@B7]; [@B35]).

Herein, we aimed to identify miRNAs that might predict endocrine resistance in luminal BrC patients undergoing ET, by comparing expression levels between BrC samples of patients that developed endocrine resistance with those that did not, after long-term follow-up. Expression levels of the miRNAs identified might allow for stratification of luminal BrC cases into a low-risk patient subgroup, for which additional adjuvant systemic treatment can be safely omitted, and a high-risk group comprising patients at high risk for recurrence, allowing for detection of resistance to ET at an early stage.

Materials and Methods {#s2}
=====================

Patients and Samples Collection {#s2_1}
-------------------------------

For this study, 139 BrC tissue samples were prospectively collected, after informed consent, from patients with luminal BrC and without metastasis at diagnosis, aged between 41 and 75 years, submitted to adjuvant ET (with or without other adjuvant modalities), after first-line surgical treatment, from 1995 to 2002 at the Portuguese Oncology Institute of Porto (IPO-Porto). Furthermore, 26 normal breast tissue samples were collected from reduction mammoplasties of contralateral breast from BrC patients. All these specimens were obtained from patients without BrC hereditary syndrome and no evidence of preneoplastic/neoplastic lesions. After surgical resection, samples were immediately frozen at −80°C. Relevant clinical and pathological data were retrieved from patients' charts. Five-micrometer frozen sections were cut and stained with hematoxylin--eosin (H&E) staining for confirmation of BrC by an experienced pathologist, ensuring that samples contained at least 70% of tumor cells, and confirm that tissues obtained from reduction mammoplasties harbored normal epithelial cells. This study was approved by institutional ethical committee (CES-IPOFG-120/015).

BrC Subtyping {#s2_2}
-------------

IHC was performed to identify the molecular subtype of each tumor tissue included in this study. Commercially available antibodies were used for ER (Clone 6F11, mouse, Leica), PR (Clone 16, mouse, Leica), HER2 (Clone 4B5, rabbit, Roche), and Ki-67 (Clone MIB-1, mouse, Dako). IHC was carried out in BenchMark ULTRA (Ventana, Roche) using ultraView Universal DAB Detection Kit (Ventana, Roche) according to the manufacturer's instructions. Each case was evaluated by an experienced pathologist; it was classified according to the College of American Pathologists recommendations ([@B17]) and categorized according to ESMO guidelines ([@B50]). Cutoffs for Ki-67 and PR expression were set at 15% and 25% of positive cells, respectively, according to the optimized protocols of Department of Pathology.

RNA Extraction From Fresh Frozen Tissues {#s2_3}
----------------------------------------

Total RNA was extracted from fresh frozen tissues using the TRIzol^®^ Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. RNA concentrations and purity ratios were ascertained using a NanoDrop Lite spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), and RNA samples were stored at −80ºC.

MiRNA cDNA Synthesis {#s2_4}
--------------------

cDNA synthesis was performed in a Veriti^®^ Thermal Cycler (Applied Biosystems, Foster City, CA, USA) using miRCURY LNA™ Universal RT microRNA PCR (Exiqon, Vedbaek, Denmark) following the manufacturer's instructions. cDNA samples were then stored at −20ºC.

Global Focus MiRNA PCR Panel {#s2_5}
----------------------------

Global miRNAs' expression was evaluated using a Cancer Focus microRNA PCR Panel, 384-well (V4.R) (Exiqon). Each plate, besides containing 80 lyophilized LNA™ miRNA primer sets focusing on cancer-relevant human miRNAs, also contained interplate calibrators, candidate reference genes \[miRNAs and small nuclear RNAs (snRNAs)\], and one water blank. In each well, 0.05 μl of cDNA previously synthesized, 5 μl of SYBR^®^ Green master mix (Exiqon), and 4.95 μl of nuclease-free water (Exiqon) were added. Quantitative reverse transcription polymerase chain reactions (RT-qPCR) were performed in the LightCycler 480 instrument (Roche Diagnostics, Manheim, Germany) according to the following conditions: 95ºC for 10 min and 45 cycles at 95ºC for 10 s and 60ºC for 1 min.

The median values of *miR-103a-3p*, *miR-107*, *miR-191-5p*, and *SNORD38B* were used for normalization, as these genes were the most stably expressed candidate reference genes ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). Differences in expression values for target miRNAs were calculated using the 2^−ΔΔCT^ method. The selection of deregulated miRNAs for further validation was performed considering prominent fold change, good sensitivity for qRT-PCR detection (Ct values, in general, below 30), and novelty.

Individual Assays {#s2_6}
-----------------

Initially, cDNA samples were diluted 80× in sterile distilled water (B. Braun, Melsungen, Germany). Then, on ice, *per* each well of a 384-well plate, the following were added: 5 μl of NZYSpeedy qPCR Green Master Mix (2×) (NZYTECH, Portugal), 1 μl of miRNA specific primer mix (microRNA LNA™ PCR primer set, Exiqon), and 4 μl of previously diluted cDNA. Each amplification reaction was performed in triplicate on a LightCycler 480 instrument (Roche Diagnostics, Manheim, Germany). Each plate also contained two negative template controls. RT-qPCR protocol consisted of a denaturation step at 95ºC for 2 min, followed by 40 amplification cycles at 95ºC for 5 s and 60ºC for 20 s. Melting curve analysis was performed according to the instrument's manufacturer's recommendations.

*SNORD38B* was used as a reference gene for data normalization, as this gene was the most stably expressed over the whole range of the samples used for the global expression assay. Notwithstanding, the stability of *SNORD38B* expression was empirically validated in additional samples. Relative miRNA expression in each sample was calculated by the 2^−ΔΔCT^ method (the target sequences of mature miRNAs analyzed are provided in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}).

Statistical Analysis {#s2_7}
--------------------

Statistical analysis was performed using SPSS software (SPSS Version 24.0, Chicago, IL), and two-tailed *p* values were considered statistically significant when *p* \< 0.05. Graphs were constructed using GraphPad 6 Prism (GraphPad Software, USA).

### MiRNA Expression Analysis {#s2_7_1}

Fold changes for single miRNAs were calculated using the 2^−ΔΔCT^ method ([@B31]).

### Association Between MiRNA Expression and Clinicopathological Features {#s2_7_2}

To ascertain statistical significance for continuous variables, comparisons were made between independent samples and non-parametric Mann--Whitney *U* tests were performed. Spearman nonparametric correlation test was performed to assess the association between continuous variables. Chi-square test or Fisher's exact test were used as appropriate to compare proportions between two groups.

### Survival Analysis {#s2_7_3}

Some clinicopathological features were grouped, including pT stage (T1 and T2 and T3 and T4), pN stage (N0 and N1 and N2 and N3), and grade \[grade (G)1 and G2 and G3\] ([@B28]). Age was categorized into four groups (≤44, 45--64, 65--74, and ≥75), and miRNA expression levels were categorized according to 25th or 75th percentile. All survival analyses were restricted to 15 years of follow-up. Cox regression univariable and multivariable models were computed to assess standard clinicopathological variables and miRNA prognostic value. Hazard ratios (HRs) along with respective 95% confidence interval (95% CIs) were reported. Multivariable Cox models only included the statistically significant variables. Kaplan--Meier with log rank test was used to construct and compare survival curves according to categorized miRNA expression levels. Endocrine resistance-free survival (ERFS) was defined as the time between surgery and the recurrence dates. Recurrences occurring after 12 months of completing ET were not considered events for this analysis. Disease-free survival (DFS) was defined as the time between surgery date and recurrence date. Distant metastasis-free survival (DMFS) was defined as the time between surgery and the development of distant metastases. For prognostic assessment of miRNAs combined in panels, the miRNAs that remained statistically significant in multivariable analysis were differently combined, considering the same categories used in previous survival analysis (expression above or below P25). The best panels were selected based on the individual markers value in the Cox model: better HR, smaller 95% CI and *p* value, as well as value in stratified analysis.

Results {#s3}
=======

Characteristics of Study Populations {#s3_1}
------------------------------------

The discovery cohort (*n* = 16), used for global expression assay analysis, consisted of four luminal A and four luminal B tumors from BrC patients who relapsed, and the same number of patients who did not relapse after adjuvant ET. Patients who relapsed during adjuvant ET or within the first 12 months of completing adjuvant ET were considered endocrine-resistant ([**Table 2**](#T2){ref-type="table"}).

###### 

Clinical and pathological data of luminal tumors included in the discovery cohort.

                                     Molecular subtype   Age at diagnosis   Grade   Stage   ChT                    RT     Recurrency site   Endocrine-resistant
  ---------------------------------- ------------------- ------------------ ------- ------- ---------------------- ------ ----------------- ---------------------
  **Patients who relapsed**          **Luminal A**       82                 G2      IIIA    NO                     NO     Liver             YES
  41                                 G3                  IIA                YES     YES     Bone                   YES                      
  60                                 UNKN                IA                 NO      YES     Contralateral breast   NO                       
  43                                 G2                  IIB                YES     YES     Lymph nodes            NO                       
  **Luminal B**                      65                  G3                 IIIC    YES     YES                    Lung   YES               
  63                                 G2                  IIIA               NO      YES     Bone                   YES                      
  67                                 G2                  IIB                NO      NO      Bone                   NO                       
  66                                 G3                  IIIA               NO      NO      Locoregional           NO                       
  **Patients who did not relapse**   **Luminal A**       70                 G3      IIB     NO                     YES    n.a.              n.a.
  68                                 G2                  IIB                NO      YES                                                     
  69                                 G2                  IIIA               NO      NO                                                      
  69                                 G2                  IA                 NO      YES                                                     
  **Luminal B**                      65                  G3                 IIIC    YES     YES                                             
  72                                 G3                  IIIC               NO      YES                                                     
  70                                 G1                  IIB                NO      YES                                                     
  73                                 G1                  IIIC               NO      YES                                                     

ChT, chemotherapy; RT, radiotherapy; UNKN, unknown; n.a., not applicable.

The validation cohort was composed of a total of 149 subjects, comprising 123 luminal BrC and 26 normal breast tissues. Among 34 cancer patients that recurred during follow-up time, 20 were considered endocrine-resistant. Clinical and pathological characteristics of patients and controls included in this study are shown in [**Table 3**](#T3){ref-type="table"}. Endocrine-sensitive and endocrine-resistant groups did not significantly differ concerning age distribution (*p* = 0.136). As expected, most of the endocrine-resistant cases were classified as luminal B (*p* = 0.011) and depicted high Ki-67 *index* (*p* = 0.001). Moreover, this group also showed a higher number of high-grade (G3) cases (*p* = 0.027). For the remaining clinicopathological features or treatment modalities, no significant differences were depicted.

###### 

Clinical and pathological data of luminal tumors and normal breast samples included in the validation cohort.

  -------------------------------------------------------------------------------------------------
  Clinipathological features              Endocrine-sensitive   Endocrine-resistant   NBr
  --------------------------------------- --------------------- --------------------- -------------
  **Patients** (n)                        103                   20                    26

  **Age median** (range)                  61 (43--73)           59 (41--75)           54 (40--70)

  61 (41--75)                                                                         

  **Molecular subtype (%)**\              47 (45.6)\            3 (15.0)\             n.a.
   Luminal A\                             56 (54.4)             17 (85.0)             
   Luminal B                                                                          

  **Histological type (%)**\              89 (86.4)\            17 (85.0)\            n.a.
   Invasive carcinoma of NST (IDC)\       5 (4.8)\              2 (10.0)\             
   Invasive lobular carcinoma\            1 (1.0)\              1 (5.0)\              
   Other special subtype carcinoma\       8 (7.8)               0 (0.0)               
   Mixed type carcinoma                                                               

  **Progesterone receptor status (%)**\   85 (82.5)\            13 (65.0)\            n.a.
   Positive\                              18 (17.5)             7 (35.0)              
   Negative                                                                           

  **HER2 receptor status (%)**\           9 (8.7)\              5 (25.0)\             n.a.
   Positive\                              94 (91.3)             15 (75.0)             
   Negative                                                                           

  **Ki-67 index (%)**\                    78 (75.7)\            6 (30.0)\             n.a.
   \<15%\                                 20 (19.4)\            10 (50.0)\            
   \>15%\                                 5 (4.9)               4 (20.0)              
   UNKN                                                                               

  **Grade (%)**\                          16 (15.5)\            0 (0.0)\              n.a.
   G1\                                    53 (51.5)\            8 (40.0)\             
   G2\                                    28 (27.2)\            10 (50.0)\            
   G3\                                    6 (5.8)               2 (10.0)              
   Not determined                                                                     

  **Pathological T Stage (%)**\           30 (29.1)\            5 (25.0)\             n.a.
   pT1\                                   50 (48.5)\            13 (65.0)\            
   pT2\                                   3 (2.9)\              0 (0.0)\              
   pT3\                                   5 (4.9)\              1 (5.0)\              
   pT4\                                   15 (14.6)             1 (5.0)               
   Not determined                                                                     

  **Pathological N Stage (%)**\           40 (38.8)\            8 (40.0)\             n.a.
   pN0\                                   38 (36.9)\            8 (40.0)\             
   p N1\                                  7 (6.8)\              3 (15.0)\             
   p N2\                                  3 (2.9)\              0 (0.0)\              
   p N3\                                  15 (14.6)             1 (5.0)               
   Not determined                                                                     

  **Adjuvant RT**\                        76 (73.8)\            17 (85.0)\            n.a.
   Yes\                                   17 (16.5)\            3 (15.0)\             
   No\                                    10 (9.7)              0 (0.0)               
   Not determined                                                                     

  **Adjuvant ChT**\                       37 (35.9)\            11 (55.0)\            n.a.
   Yes\                                   50 (48.6)\            7 (35.0)\             
   No\                                    16 (15.5)             2 (10.0)              
   Not determined                                                                     
  -------------------------------------------------------------------------------------------------

NBr, normal breast tissues; NST, no special type; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor receptor 2; G, grade; RT, radiotherapy; ChT, chemotherapy; n.a., not applicable.

Global Focus MiRNA PCR Panel Analysis {#s3_2}
-------------------------------------

In the global expression assay, one luminal A case with recurrence was excluded from the analysis, due to low RT-qPCR success rate (25% of the miRNAs did not amplify, and the remaining showed Ct values higher than 30). Likewise, 3 (*miR-202-3p*, *-206*, and *-20b-5p*) out of the 80 miRNAs were excluded due to low real-time PCR success rates. MiRNAs with fold variation values higher than 1 were selected, resulting in a panel comprising 56 miRNAs ([**Table 4**](#T4){ref-type="table"}).

###### 

MiRNAs with fold variation values higher than 1 in the global expression assay.

  LumA Rec *vs*. LumA NRec   LumB Rec *vs*. LumB NRec   Lum Rec *vs*. Lum NRec                                  
  -------------------------- -------------------------- ------------------------ --------- -------------------- ---------
  **miR-196a-5p**            2.1281                     **miR-9-5p^1^**          2.5978    **miR-9-5p^1^**      1.4448
  **miR-181b-5p**            −1.0119                    **miR-210-3p^1^**        1.7178    **miR-149-3p^1^**    1.23995
  **miR-130a-3p^1^**         −1.0519                    **miR-182-5p^2^**        1.6028    **miR-126-3p**       −1.0909
  **miR-29b-3p**             −1.1169                    **miR-7-5p^1^**          1.3978    **miR-1**            −1.1352
  **let-7b-5p**              −1.1269                    **miR-200c-3p**          1.2778    **miR-148a-3p**      −1.1419
  **let-7i-5p**              −1.1369                    **miR-31-5p^1^**         1.0928    **miR-30d-5p**       −1.2139
  **miR-106b-5p**            −1.1419                    **miR-221-3p**           1.0128    **miR-181a-5p^2^**   −1.4322
  **miR-132-3p^1^**          −1.1519                    **miR-125b-5p**          −1.0172   **miR-200a-3p**      −1.5732
  **miR-26b-5p**             −1.1619                    **miR-146a-5p**          −1.0372   **miR-205-5p^2^**    −2.3252
  **miR-19b-3p**             −1.1769                    **miR-181a-5p^2^**       −1.0622                        
  **miR-192-5p^1^**          −1.1969                    **miR-205-5p^2^**        −1.1172                        
  **let-7g-5p**              −1.2019                    **miR-1^1^**             −1.1472                        
  **miR-16-5p**              −1.2319                    **miR-10b-5p**           −1.4022                        
  **miR-15a-5p**             −1.2619                                                                            
  **miR-106a-5p**            −1.2669                                                                            
  **miR-20a-5p**             −1.2769                                                                            
  **let-7a-5p**              −1.3019                                                                            
  **miR-21-5p**              −1.3169                                                                            
  **miR-214-3p**             −1.3569                                                                            
  **miR-93-5p**              −1.4119                                                                            
  **let-7f-5p**              −1.4369                                                                            
  **miR-222-3p**             −1.4419                                                                            
  **miR-200c-3p**            −1.4719                                                                            
  **miR-155-5p**             −1.5119                                                                            
  **let-7e-5p**              −1.5119                                                                            
  **let-7d-5p**              −1.5619                                                                            
  **miR-148a-3p**            −1.6369                                                                            
  **miR-181a-5p^2^**         −1.6519                                                                            
  **miR-23b-3p**             −1.7569                                                                            
  **miR-23a-3p**             −1.8069                                                                            
  **miR-19a-3p**             −1.8519                                                                            
  **miR-1^1^**               −1.8869                                                                            
  **miR-221-3p**             −1.9319                                                                            
  **miR-195-5p**             −1.9369                                                                            
  **miR-18a-5p^1^**          −1.9919                                                                            
  **miR-30c-5p^2^**          −2.0419                                                                            
  **miR-182-5p^2^**          −2.1119                                                                            
  **miR-186-5p^1^**          −2.1319                                                                            
  **miR-141-3p**             −2.1619                                                                            
  **miR-17-5p^1^**           −2.1919                                                                            
  **miR-30d-5p**             −2.2769                                                                            
  **miR-30b-5p^2^**          −2.4819                                                                            
  **miR-101-3p**             −2.5319                                                                            
  **miR-200b-3p^2^**         −3.0019                                                                            
  **miR-92b-3p^1^**          −3.1069                                                                            
  **miR-200a-3p**            −3.2169                                                                            
  **miR-205-5p^2^**          −4.1269                                                                            

^1^Cps higher than 30. ^2^miRNAs chosen for further validation. Lum, luminal; Rec, recurrent.

Gene-Specific Assays {#s3_3}
--------------------

From the global expression assay analysis, *miR-30b-5p*, *miR-30c-5p*, *miR-181a-5p*, *miR-182-5p*, *miR-200b-3p*, and *miR-205-5p* were selected for further validation. All these miRNAs disclosed prominent fold change and good sensitivity for qRT-PCR detection, with different ranges of expression. *MiR-30b-5p* was chosen because several studies focused on other members of the *miR-30 family (miR-30f)* and, to the best of our knowledge, its predictive potential for ET had not been assessed previously ( [@B10]; [@B4]; [@B67]; [@B15]; [@B61]). *MiR-181a-5p* and *miR-200b-3p* were selected to confirm the reported association with endocrine resistance in *in vitro* studies ([@B22]; [@B33]; [@B34]; [@B58]; [@B35]). Furthermore, *miR-182-5p* was also selected to better ascertain its role in endocrine resistance due to controversial results in global focus miRNA PCR panel, since it was overexpressed in luminal B tumors from recurrent patients and downregulated in luminal A tumors from recurrent patients. Finally, *miR-30c-5p* was chosen as a positive control since higher expression levels of this miRNA had been positively associated with benefit of ET, in multivariate analysis, in advanced ER-positive BrC ([@B47]).

Except for *miR-205-5p* expression (*p* = 0.001), *miR-181a-5p* (*p* = 0.004), *miR-182-5p* (*p* \< 0.001), and *miR-200b-3p* (*p* \< 0.001), expression levels were significantly higher in luminal BrC tissues than in normal breast tissues ([**Figure 1**](#f1){ref-type="fig"}), whereas no differences were depicted for the levels of the remaining miRNAs. Nonetheless, *miR-30b-5p* (*p* = 0.031), *miR-30c-5p* (*p* = 0.002), and *miR-200b-3p* (*p* = 0.021) were significantly downregulated in endocrine-resistant BrC samples compared to endocrine-sensitive tumors ([**Figure 2**](#f2){ref-type="fig"}).

![Scatterplots of *miR-181a-5p* **(A)**, *miR-182-5p* **(B)**, *miR-200b-3p* **(C)**, and *miR-205-5p* **(D)** relative expression levels in luminal tumor tissues and normal breast tissues. A \*\* denotes *p* value \<0.01 and a \*\*\* denotes *p* value \<0.001 by non-parametric Mann--Whitney *U* test. *Y*-axis denotes 2^−ΔΔCT^ values multiplied by 1000. Red horizontal lines represent median value.](fgene-10-00815-g001){#f1}

![Scatterplots of *miR-30c-5p* **(A)**, *miR-30b-5p* **(B)**, and *miR-200b-3p* **(C)** relative expression levels in tumor tissues from endocrine-sensitive and -resistant patients. A \* denotes *p* value \<0.05 and a \*\* denotes *p* value \<0.01 by non-parametric Mann--Whitney *U* test. *Y*-axis denotes 2^−ΔΔCT^ values multiplied by 1000. Red horizontal lines represent median value.](fgene-10-00815-g002){#f2}

Association Between MiRNA Expression and Clinicopathological Features {#s3_4}
---------------------------------------------------------------------

Higher *miR-30b-5p* and m*iR-30c-5p* expression levels were found in tumors lacking HER2 overexpression (HER2-negative) (*p* = 0.010, *p* = 0.014, respectively). Conversely, lower *miR-205-5p* expression levels were found in high grade (G3) BrC (*p* = 0.009) compared to G1/G2 BrC ([**Figure 3**](#f3){ref-type="fig"}). Moreover, *miR-205-5p* expression levels inversely correlated with patients' age (*R* = −0.200, *p* = 0.027).

![Scatterplots of *miR-30c-5p* relative expression levels according to HER2 *status* **(A)**, *miR-30b-5p* relative expression according to HER2 *status* **(B)**, and *miR-205-5p* relative expression according to grade **(C)**. A \* denotes *p* value \<0.05 and a \*\* denotes *p* value \<0.01 by non-parametric Mann--Whitney *U* test. Y-axis denotes 2^−ΔΔCT^ values multiplied by 1000. Red horizontal lines represent median value.](fgene-10-00815-g003){#f3}

Survival Analyses {#s3_5}
-----------------

The median follow-up time was 180 months (17.4--180 months). At 15 years of follow-up, 70 (56.9% of total) patients were alive, of whom 66 (53.7% of total) had no evidence of cancer. Moreover, from the 53 patients (43.1% of total) who died, death was due to BrC in 30 (24.4% of total).

Overall, in univariable analysis, most standard clinicopathological parameters were significantly associated with ERFS. Specifically, patients with HER2 positivity (HR = 2.91, *p* = 0.039), high Ki-67 *index* (HR = 5.59, *p* = 0.001), high grade (G3) (HR = 2.84, *p* = 0.028), and luminal B subtype (HR = 4.48, *p* = 0.017) disclosed shorter ERFS. Importantly, the same was observed for patients with lower *miR-30c-5p*, *miR-30b-5p*, *miR-182-5p*, and *miR-200b-3p* levels ([**Table 5**](#T5){ref-type="table"}, [**Figure 4**](#f4){ref-type="fig"}). In multivariable analysis, all miRNAs remained independent predictors of ERFS adjusted for Ki-67 *index* ([**Table 5**](#T5){ref-type="table"}). After stratification for Ki-67 *index*, *miR-30c-5p*, *miR-182-5p*, and *miR-200b-3p* only independently predicted shorter ERFS in highly proliferative tumors, whereas *miR-30b-5p* was significant in tumors with low proliferative ([**Table 6**](#T6){ref-type="table"}).

###### 

Univariable and multivariable Cox regression models assessing the association between microRNAs expression levels and clinical outcome.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Model                                    Outcome                                 Variable                                HR (95% CI)            *p* value
  ---------------------------------------- --------------------------------------- --------------------------------------- ---------------------- -----------
  **Univariate Analysis**                  **ERFS**                                miR-30c-5p expression categorized\      1\                     0.005
                                                                                   ≤P25\                                   0.283 (0.117--0.683)   
                                                                                   \>P25                                                          

  miR-30b-5p expression categorized\       1\                                      0.015                                                          
  ≤P25\                                    0.338 (0.141--0.812)                                                                                   
  \>P25                                                                                                                                           

  miR-182-5p expression categorized\       1\                                      0.001                                                          
  ≤P25\                                    0.207 (0.082--0.519)                                                                                   
  \>P25                                                                                                                                           

  miR-200b-3p expression categorized\      1\                                      0.003                                                          
  ≤P25\                                    0.245 (0.098--0.615)                                                                                   
  \>P25                                                                                                                                           

  **DFS**                                  miR-30c-5p expression categorized\      1\                                      0.013                  
                                           ≤P25\                                   0.422 (0.214--0.832)                                           
                                           \>P25                                                                                                  

  miR-30b-5p expression categorized\       1\                                      0.025                                                          
  ≤P25\                                    0.458 (0.231--0.907)                                                                                   
  \>P25                                                                                                                                           

  miR-182-5p expression categorized\       1\                                      0.001                                                          
  ≤P25\                                    0.259 (0.120--0.558)                                                                                   
  \>P25                                                                                                                                           

  miR-200b-3p expression categorized\      1\                                      0.001                                                          
  ≤P25\                                    0.267 (0.127--0.562)                                                                                   
  \>P25                                                                                                                                           

  miR-205-5p expression categorized\       1\                                      0.043                                                          
  ≤P25\                                    0.494 (0.250--0.979)                                                                                   
  \>P25                                                                                                                                           

  **DMFS**                                 miR-182-5p expression categorized\      1\                                      0.017                  
                                           ≤P25\                                   0.356 (0.153--0.828)                                           
                                           \>P25                                                                                                  

  miR-200b-3p expression categorized\      1\                                      0.012                                                          
  ≤P25\                                    0.354 (0.158--0.794)                                                                                   
  \>P25                                                                                                                                           

  **Multivariate analysis**                **ERFS**                                miR-30c-5p expression categorized^1^\   1\                     0.006
                                                                                   ≤P25\                                   0.223 (0.076--0.649)   
                                                                                   \>P25                                                          

  miR-30b-5p expression categorized^1^\    1\                                      0.047                                                          
  ≤P25\                                    0.344 (0.120--0.987)                                                                                   
  \>P25                                                                                                                                           

  miR-182-5p expression categorized^1^\    1\                                      0.002                                                          
  ≤P25\                                    0.174 (0.057--0.529)                                                                                   
  \>P25                                                                                                                                           

  miR-200b-3p expression categorized^1^\   1\                                      0.003                                                          
  ≤P25\                                    0.184 (0.060--0.561)                                                                                   
  \>P25                                                                                                                                           

  **DFS**                                  miR-30c-5p expression categorized^1^\   1\                                      0.026                  
                                           ≤P25\                                   0.417 (0.193--0.902)                                           
                                           \>P25                                                                                                  

  miR-182-5p expression categorized^1^\    1\                                      \<0.001                                                        
  ≤P25\                                    0.190 (0.078--0.463)                                                                                   
  \>P25                                                                                                                                           

  miR-200b-3p expression categorized^1^\   1\                                      0.001                                                          
  ≤P25\                                    0.231 (0.094--0.564)                                                                                   
  \>P25                                                                                                                                           

  **DMFS**                                 miR-182-5p expression categorized^2^\   1\                                      0.020                  
                                           ≤P25\                                   0.302 (0.111--0.825)                                           
                                           \>P25                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Cox regression model adjusted for Ki-67 index. ^2^Cox regression models adjusted for grade. ERFS, endocrine resistance-free survival; DFS, disease-free survival; DMFS, distant metastasis-free survival.

![Endocrine resistance-free survival (ERFS) curves (Kaplan--Meier with log rank test) of *miR-30b-5p* **(A)**, *miR-30c-5p* **(B)**, *miR-182-5p* **(C)**, and *miR-200b-3p* **(D)**. P25, Percentile 25.](fgene-10-00815-g004){#f4}

###### 

Cox regression models stratified according to the clinicopathological features with statistical significance in the multivariate analysis.

  ---------------------------------------------------------------------------------------------------------------------------------
  Outcome             Layering Variable                     Variable                             HR (95% CI)            *p* value
  ------------------- ------------------------------------- ------------------------------------ ---------------------- -----------
  **ERFS**            Ki-67 index \<15%                     miR-30c-5p expression categorized\   --                     0.175
                                                            ≤P25\                                                       
                                                            \>P25                                                       

  Ki-67 index \>15%   miR-30c-5p expression categorized\    1\                                   0.007                  
                      ≤P25\                                 0.171 (0.047--0.619)                                        
                      \>P25                                                                                             

  Ki-67 index \<15%   miR-30b-5p expression categorized\    1\                                   0.028                  
                      ≤P25\                                 0.149 (0.027--0.813)                                        
                      \>P25                                                                                             

  Ki-67 index \>15%   miR-30b-5p expression categorized\    --                                   0.334                  
                      ≤P25\                                                                                             
                      \>P25                                                                                             

  Ki-67 index \<15%   miR-182-5p expression categorized\    --                                   0.537                  
                      ≤P25\                                                                                             
                      \>P25                                                                                             

  Ki-67 index \>15%   miR-182-5p expression categorized\    1\                                   0.003                  
                      ≤P25\                                 0.137 (0.037--0.503)                                        
                      \>P25                                                                                             

  Ki-67 index \<15%   miR-200b-3p expression categorized\   --                                   0.610                  
                      ≤P25\                                                                                             
                      \>P25                                                                                             

  Ki-67 index \>15%   miR-200b-3p expression categorized\   1\                                   0.002                  
                      ≤P25\                                 0.121 (0.033--0.447)                                        
                      \>P25                                                                                             

  **DFS**             Ki-67 index \<15%                     miR-30c-5p expression categorized\   --                     0.247
                                                            ≤P25\                                                       
                                                            \>P25                                                       

  Ki-67 index \>15%   miR-30c-5p expression categorized\    1\                                   0.020                  
                      ≤P25\                                 0.268 (0.088--0.815)                                        
                      \>P25                                                                                             

  Ki-67 index \<15%   miR-182-5p expression categorized\    --                                   0.141                  
                      ≤P25\                                                                                             
                      \>P25                                                                                             

  Ki-67 index \>15%   miR-182-5p expression categorized\    1\                                   0.003                  
                      ≤P25\                                 0.137 (0.037--0.503)                                        
                      \>P25                                                                                             

  Ki-67 index \<15%   miR-200b-3p expression categorized\   --                                   0.202                  
                      ≤P25\                                                                                             
                      \>P25                                                                                             

  Ki-67 index \>15%   miR-200b-3p expression categorized\   1\                                   0.002                  
                      ≤P25\                                 0.121 (0.033--0.447)                                        
                      \>P25                                                                                             

  **DMFS**            Grades 1 and 2                        miR-182-5p expression categorized\   1\                     0.022
                                                            ≤P25\                                0.255 (0.079--0.823)   
                                                            \>P25                                                       

  Grade 3             miR-182-5p expression categorized\    --                                   0.076                  
                      ≤P25\                                                                                             
                      \>P25                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------

ERFS, endocrine resistance-free survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; HER2, human epidermal growth factor 2 receptor.

Regarding DFS, in addition to HER2 positivity (HR = 2.40, *p* = 0.039), high Ki-67 *index* (HR = 3.01, *p* = 0.003), and high grade (G3) (HR = 2.65, *p* = 0.006), lower *miR-30c-5p*, *miR-30b-5p*, *miR-182-5p*, *miR-200b-3p*, and *miR-205-5p* expression levels associated with decreased DFS in univariable analysis ([**Table 5**](#T5){ref-type="table"}, [**Figure 5**](#f5){ref-type="fig"}). Nonetheless, in the multivariable model, only *miR-30c-5p*, *miR-200b-3p*, and *miR-182-5p* were disclosed as independent prognostic predictors adjusted for Ki-67 *index* ([**Table 5**](#T5){ref-type="table"}), and after stratification according for Ki-67 *index*, all miRNAs retained statistical significance in high Ki-67 *index* BrC patients ([**Table 6**](#T6){ref-type="table"}). Similarly, HER2 positivity (HR = 2.63, *p* = 0.024), high Ki-67 *index* (HR = 2.48, *p* = 0.021), and high grade (G3) (HR = 2.69, *p* = 0.007) associated with worse DMFS, along with lower *miR-182-5p* and *miR-200b-3p* expression levels, in univariate analysis ([**Table 5**](#T5){ref-type="table"}). However, only *miR-182-5p* retained statistical significance when adjusted for tumor grade in multivariable analysis ([**Table 5**](#T5){ref-type="table"}). After stratification by tumor grade, *miR-182-5p* showed prognostic value in patients harboring low/intermediate-grade tumors ([**Table 6**](#T6){ref-type="table"}).

![Disease-free survival (DFS) curves (Kaplan--Meier with log rank test) of *miR-30b-5p* **(A)**, *miR-30c-5p* **(B)**, *miR-182-5p* **(C)**, *miR-200b-3p* **(D)**, and *miR-205-5p* **(E)**. P25, Percentile 25.](fgene-10-00815-g005){#f5}

Furthermore, the prognostic value of the miRNAs that individually predicted ERFS and DFS was assessed when combined in panels. For ERFS, the patients were grouped as expression above P25 for 3 or 4 miRNAs versus expression below P25 for 2 or more miRNAs. Thus, the combination of m*iR-30c-5p*, *miR-30b-5p*, *miR-182-5p*, and *miR-200b-3p* was shown as the best predictors of ERFS. Patients with miRNAs' expression below P25 displayed a shorter ERFS (*p* \< 0.001), paralleling the results obtained in single miRNAs analysis ([**Figure 6**](#f6){ref-type="fig"}, [**Table 7**](#T7){ref-type="table"}). In multivariable analysis, miRNAs combined in panel were found to be independent ERFS predictors after Ki-67 *index* stratification ([**Table 7**](#T7){ref-type="table"}). Regarding DFS, the best predictive panel was composed of *miR-182-5p* and *miR-200b-3p*. The patients were grouped as expression above P25 for both miRNAs versus expression below P25 for at least one miRNA. Patients with both miRNAs' expression levels above P25 showed longer DFS (*p* \< 0.001) ([**Figure 6**](#f6){ref-type="fig"}, [**Table 7**](#T7){ref-type="table"}). In multivariable analysis, miRNAs combined in panel remained independent DFS predictors, although only in cases with high Ki-67 *index* ([**Table 7**](#T7){ref-type="table"}).

![ERFS curves (Kaplan--Meier with log rank test) of combined *miR-30b-5p*, *miR-30c-5p*, *miR-182-5p* and *miR200b-3p* **(A)** and DFS curves (Kaplan--Meier with log rank test) of combined *miR-182-5p* and *miR-200b-3p* panel **(B)**.](fgene-10-00815-g006){#f6}

###### 

Univariable and multivariable Cox regression models assessing the association between combined microRNAs expression panel and clinical outcome.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model                       Outcome                       Layering Variable               Variable                        HR (95% CI)            *p* value
  --------------------------- ----------------------------- ------------------------------- ------------------------------- ---------------------- -----------
  **Univariate Analysis**     ERFS                          NA                              **Combined miRNA panel**\       1\                     \<0.001
                                                                                            2 or more miRNAs below P25\     0.183 (0.075--0.448)   
                                                                                            3 or 4 miRNAs above P25                                

  DFS                         NA                            **Combined miRNA panel**\       1\                              \<0.001                
                                                            1 or 2 miRNAs below P25\        0.283 (0.139--0.575)                                   
                                                            All miRNAs above P25                                                                   

  **Multivariate Analysis**   ERFS                          NA                              **Combined miRNA panel** ^1^\   1\                     \<0.001
                                                                                            2 or more miRNAs below P25\     0.126 (0.042--0.380)   
                                                                                            3 or 4 miRNAs above P25                                

  DFS                         NA                            **Combined miRNA panel** ^1^\   1\                              \<0.001                
                                                            1 or 2 miRNAs below P25\        0.205 (0.088--0.476)                                   
                                                            All miRNAs above P25                                                                   

  **Multivariate Analysis**   ERFS                          Ki-67 *index* \<15%             **Combined miRNA panel**\       1\                     0.018
                                                                                            2 or more miRNAs below P25\     0.129 (0.024--0.703)   
                                                                                            3 or 4 miRNAs above P25                                

  Ki-67 *index* \>15%         **Combined miRNA panel**\     1\                              0.002                                                  
                              2 or more miRNAs below P25\   0.134 (0.037--0.485)                                                                   
                              3 or 4 miRNAs above P25                                                                                              

  DFS                         Ki-67 *index* \<15%           **Combined miRNA panel**\       --                              0.184                  
                                                            1 or 2 miRNAs below P25\                                                               
                                                            All miRNAs above P25                                                                   

  Ki-67 *index* \>15%         **Combined miRNA panel**\     1\                              0.001                                                  
                              1 or 2 miRNAs below P25\      0.100 (0.027--0.367)                                                                   
                              All miRNAs above P25                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Cox regression model adjusted for Ki-67 index. ERFS, endocrine resistance-free survival; DFS, disease-free survival; NA, not applicable.

Discussion {#s4}
==========

BrC remains the most common malignancy in women and a major cause of morbidity and mortality ([@B5]). De-escalation of both systemic and local adjuvant treatment, paralleling trends in surgery, is critical to provide patient-tailored treatment and avoid harmful side effects ([@B26]; [@B50]). Indeed, identification of luminal BrC patients with low recurrence risk after or while on ET, for which additional adjuvant systemic treatment can be safely omitted, is very important. On the other hand, identification of high-risk luminal BrC patients requiring more aggressive treatment regimens is critical to avoid recurrence and subsequent metastatic disease, which currently affects approximately 40% of luminal BrC patients after adjuvant ET ([@B19]; [@B41]; [@B39]). Thus, identification of biomarkers providing predictive and prognostic information in this group of patients is clinically relevant. Assessment of specific miRNAs' expression deregulation, which has been associated with several mechanisms underlying endocrine resistance and sensitivity ([@B37]; [@B38]), might provide such kind of information. Nonetheless, most of those studies have been performed in cancer cell lines and display several limitations, including absence of epithelial--stromal and tumor--host interactions, that could modulate sensitivity *in vivo* ([@B51]). Conversely, tissue analysis from patients treated with ET may allow for broader insight into biologically and clinically relevant miRNAs that may serve as markers of response or resistance to ET. Thus, we focused on the identification of aberrantly expressed miRNAs in endocrine-resistant BrC, exploring its predictive and prognostic value in luminal BrC patients treated with adjuvant ET.

The first step of this study consisted on the profiling of miRNAs' expression patterns, looking for differences between endocrine-sensitive and endocrine-resistant luminal BrC. Hence, *miR-30c-5p*, *miR-30b-5p*, *miR-181a-5p*, *miR-182-5p*, *miR-200b-3p*, and *miR-205-5p* were selected for validation in a larger set of luminal BrC and normal breast tissues. Upregulation of *miR-181a-5p* and *miR-182-5p* and downregulation of *miR-205-5p* in this BrC tissue cohort was consistent with previous reports ([@B25]; [@B29]; [@B65]), providing indirect validation of our methodological approach. However, *miR-200b-3p* downregulation in tumor compared to normal tissues has been previously reported ([@B63]; [@B62]). Nevertheless, these studies have used non-cancerous tissues from breasts harboring carcinoma as controls, which may not represent truly normal breast tissues. Our results also confirm the biomarker potential of *miR-30c-5p*, which was found downregulated in endocrine-resistant BrC patients and independently predicted ERFS in luminal BrC patients, particularly in highly proliferative tumors. Moreover, *miR-30c-5p* expression correlated with HER2 *status*, one of the most important predictive factors for ET sensitivity ([@B27]). In fact, HER2 signaling activation has been widely implicated in endocrine resistance ([@B36]; [@B1]). Moreover, *miR-200b-3p* expression levels displayed the same trend and, together with *miR-30b-5p* and *miR-182-5p*, also independently predicted ERFS in luminal BrC patients. Importantly, we were able to validate in primary BrC the association between *miR-200b-3p* and endocrine-resistance, which was previously reported only in *in vitro* models ([@B35]). Interestingly, several members of *miR-30f* have been reported as markers of favorable prognosis in BrC ([@B10]; [@B4]; [@B67]; [@B15]; [@B13]) and our study also revealed that *miR-30b-5p* might be predictive of response to ET. Finally, concerning *miR-182-5p*, our results extended previous observations on the correlation with clinical benefit from therapy with tamoxifen in advanced-stage BrC, only previously demonstrated in univariable analysis ([@B47]).

In addition to their predictive value, *miR-30b-5p* and *miR-30c-5p* lower expression levels also associated with decreased DFS, although in univariable analysis only. Indeed, the role of m*iR-30f* members as tumor suppressors in BrC has been previously reported ([@B4]; [@B67]). Furthermore, decreased levels of *miR-30f* members in BrC patients have been associated with poor relapse-free survival ([@B13]). Importantly, lower *miR-182-5p* and *miR-200b-3p* expression levels independently associated with decreased DFS in highly proliferative tumors. The role of *miR-200b-3p* as a prognostic marker in BrC is not a novelty ([@B63]; [@B62]). Indeed, members of *miR-200f* are known to act as enforcers of epithelial phenotype through either Zinc finger E-box-binding homeobox (ZEB)-dependent or -independent pathways ([@B30]). Intriguingly, most *in vitro* studies consistently attributed an oncogenic role to *miR-182-5p* ([@B11]; [@B64]). Nonetheless, higher *miR-182-5p* expression levels were associated with poor clinical outcome in BrC patients ([@B53]), contrarily to our findings. It should be recalled, however, that *miR-182-5p* is a member of a miRNA family comprising three homologous, coordinately expressed, miRNAs (*miR-183*, *miR-182*, and *miR-196*), which are clustered in chromosome 7q32.2 and that members of this cluster have been associated with both pro- and anti-metastatic behavior in BrC, suggesting that *miR-183/96/182* cluster members may have divergent functions that are regulated in a context- and tissue-dependent manner ([@B32]; [@B29]; [@B23]). Furthermore, the 7q32.2 locus has been considered a metastasis suppressor locus, enduring genetic copy number losses in BrC progression ([@B45]). Thus, the association between *miR-182-5p* downregulation and worse prognosis probably results from a complex molecular scenario and additional studies are required to discriminate which members of the *miR-183/96/182* cluster might contribute and to which extent to BrC prognosis.

BrC tissues displayed higher *miR-182-5p* and *miR-200b-3p* levels compared to normal breast, although *miR-182-5p* and *miR-200b-3p* downregulation associated with shorter DMFS. Because development of solid neoplasms results from multiple sequential steps in which malignant cells undergo widespread modifications allowing for successful migration and colonization of other organs, we are tempted to speculate whether a context-dependent role of these miRNAs might contribute to the emergence of a malignant phenotype. Indeed, decreased expression of *miR-200f* members might be associated with EMT initiation, enabling cells with invasive capabilities, whereas subsequent upregulation might be associated with mesenchymal-to-epithelial transition, facilitating colonization ([@B18]; [@B21]).

Combined expression levels of *miR-30c-5p*, *miR-30b-5p*, *miR-182-5p*, and *miR-200b-3p* independently predicted ERFS, when adjusted for confounding factors (Ki-67 *index*). In fact, this combined miRNA panel was associated with ERFS in both low and highly proliferative tumors. In parallel, the *miR-182-5p*/*miR-200b-3p* panel was shown to independently predict DFS in highly proliferative tumors. As previously reported in different tumor models, the combination of miRNAs in a panel might enable a more efficient diagnostic, predictive, and prognostic model overcoming the questionable value of single miRNAs ([@B48]; [@B9]).

Although the retrospective design of the study and the relatively small number of samples of the discovery cohort constitute important limitations, our results suggest that a panel of miRNAs might be tested in primary tumor tissues to assess the likelihood of recurrence and resistance to ET in newly diagnosed luminal BrC. Nevertheless, these miRNAs need to be carefully validated, ideally in multicenter studies, to generate more conclusive results. Furthermore, *in vitro* studies, including gain- and loss-of-function assays following *in vitro* treatment with ET, are also critical to functionally characterize the role of these miRNAs. As a future perspective, we intend to evaluate the putative role of these miRNAs in tumor progression and dissemination. Additionally, we also intend to evaluate the potential role of these miRNAs in liquid biopsies, evaluating their potential as non-invasive biomarkers. Indeed, miRNAs in circulation would enable the repeated noninvasive monitoring of miRNA expression profile changes during treatment's course, which could allow for early detection of ET resistance and/or recurrence, potentially improving the management and care of luminal BrC patients.
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